There is no biological measure for wakefulness. In a narcolepsy clinical trial, a patient lies down in a dark lab while clinicians count the minutes until sleep comes. The average time in four tests ...
Narcolepsy was linked to high blood pressure, hyperlipidemia, and diabetes on top of outright cardiovascular disease events in a retrospective cohort study. Notably, patients with narcolepsy started ...
SAN DIEGO -- AXS-12 (reboxetine), an investigational treatment for narcolepsy, reduced weekly cataplexy attacks and in some cases provided complete remission, the phase III SYMPHONY study showed. From ...
ATHENS, Ga. — They were the most tense, most exciting moments of the Georgia football season, arguably the most exciting in the entire college football season: an epic game against Georgia Tech that ...
New Drug Application (NDA) submission on track for January 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome ...
Takeda is on track to submit its much-hyped narcolepsy drug to regulators this fiscal year after the orexin receptor 2 (OX2R)-selective agonist scored a pair of phase 3 wins. The Japanese pharma had ...
Takeda and Alkermes both took data from their orexin receptor 2 (OX2R)-selective agonists to Singapore this morning as the race to get a new class of narcolepsy drugs approved heats up. Takeda ...
A hormone produced by the brain, orexin, may play a central role in the functioning of the brain’s glymphatic system, which clears waste, according to a new study from the University of Oulu.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback